FDA has a drug shortage database which includes reasons for and updates on drug shortages. Today the database read, “Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from…
The Advocacy Council of the American College of Allergy, Asthma and Immunology (ACAAI) together with its sponsoring organization, the ACAAI, the American Academy of Allergy, Asthma and Immunology (AAAAI), and the American Academy of Otolaryngic Allergy (AAOA) submitted comments on the proposed changes to the physician fee schedule rule for 2019 as published in the July 27, 2018 Federal Register.
Our comments focus on four issues: (1) the cost of venom antigens used in treating allergies to stinging insects (CPT Codes 95145-95149); (2) the proposal to reduce the supply cost for inhalant antigens used in allergen immunotherapy (CPT Codes 95144 and 95165); (3) the proposed change in the allergy/immunology indirect practice cost index (IPCI) resulting from the consolidation of evaluation and management (E&M) office visit codes and the creation of a 2 separate “specialty” for E&M office visits; and (4) the multiple procedure payment reduction (MPPR) policy.
Comments were successfully uploaded to the CMS site. View the final document here.